A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)

Study Purpose

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building plans (genes) for this protein in cancer cells leads to a production of abnormal HER2 and therefore abnormal cell growth and division. The study treatment, BAY 2927088, is expected to block the mutated HER2 protein which may stop the spread of NSCLC. The main purpose of this study is to learn how well BAY 2927088 works and how safe it is compared with standard treatment, in participants who have advanced NSCLC with specific genetic changes called HER2 mutations. The study participants will receive one of the study treatments:

- BAY 2927088 twice every day as a tablet by mouth, or.

- Standard treatment in cycles of 21 days via infusion ("drip") into the vein.

The treatment will continue for as long as participants benefit from it without any severe side effects or until they or their doctor decide to stop the treatment. During the study, the doctors and their study team will:

- take imaging scans, including CT, PET, MRI, and X-rays, of different parts of the body to study the spread of cancer.

- check the overall health of the participants by performing tests such as blood and urine tests, and checking.

- heart health using an electrocardiogram (ECG) - perform pregnancy tests for women.

- ask the participants questions about how they are feeling and what adverse events they are having.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	No
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Interventional
Eligible Ages	18 Years and Over
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

- Participant must be ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signing the informed consent.

- Documented histologically or cytologically confirmed locally advanced non-squamous NSCLC, not suitable for definitive therapy or metastatic non-squamous NSCLC at screening (small cell or mixed histologies are excluded) (Stage III-IV NSCLC).

- Documented activating HER2 mutation in the tyrosine kinase domain (TKD) assessed by tissue molecular test in a CLIA-certified (US sites) or an equally accredited (outside of the US) local laboratory.

However, participants may be included at the discretion of the investigator if the laboratory performing the assay is not CLIA or similar certified but the laboratory is locally accredited.

- No prior systemic therapy for locally advanced or metastatic disease.

No prior treatment with a HER2 ex20ins-targeted therapy (e.g. poziotinib, trastuzumab deruxtecan). Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the start of screening.

- Eligible to receive treatment with the selected platinum-based doublet-chemotherapy (i.e. cisplatin/pemetrexed or carboplatin/pemetrexed) and pembrolizumab in accordance with the SmPC/Product Information.

Exclusion Criteria:

- Known history of prior malignancy except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for five years since initiation of that therapy.

Exception: the following cancer types are acceptable within five years if curatively treated or under surveillance:

- a.

in situ cancers of cervix, breast, or skin,

- b.

superficial bladder cancer (Ta, Tis and T1),

- c.

limited-stage prostate cancer,

- d.

basal or squamous cancers of the skin.

- Tumors with targetable alterations with approved available therapy, with the exception of HER2 mutation in the TKD.

- Inability to discontinue treatment with chronic systemic corticosteroids.

Participants who require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study. Replacement therapy (e.g., physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is acceptable, provided that the dose is stable for >4 weeks prior to planned start of study intervention.

- Pre-existing peripheral neuropathy that is Grade ≥2 by CTCAE (v5.0).

- History of severe hypersensitivity reaction to treatment with a monoclonal antibody.

- Prior radiotherapy outside of the brain within 21 days of planned start of study intervention.

Participants must have recovered from all radiation-related toxicities and not require corticosteroids.

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT06452277
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.	Phase 3
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Bayer
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	N/A
Principal Investigator Affiliation	N/A
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Industry
Overall Status	Not yet recruiting
Countries	Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Romania, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Advanced Non-small Cell Lung Cancer, HER2 Mutation
Study Website:	View Trial Website

Arms & Interventions

Arms

Experimental: BAY2927088

Participants will receive BAY2927088 20 mg BID until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria.

Active Comparator: Standard of care (SoC)

Participants will receive SoC (pembrolizumab in combination with platinum-based chemotherapy, in 21-day cycles per the approved labels) until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria.

Interventions

Drug: - BAY2927088

Tablet, oral

Drug: - Pembrolizumab

Intravenous (IV) infusion

Drug: - Cisplatin

IV infusion

Drug: - Carboplatin

IV infusion

Drug: - Pemetrexed

IV infusion

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Newport Beach, California

Status

Address

Hoag Memorial Hospital - Center for Research & Education

Newport Beach, California, 93663

Site Contact

Cookie	Duration	Description
CONSENT	16 years 4 months 21 days 7 hours 17 minutes	These cookies are set via embedded youtube-videos. They register anonymous statistical data on for example how many times the video is displayed and what settings are used for playback.No sensitive data is collected unless you log in to your google account, in that case your choices are linked with your account, for example if you click “like” on a video.
vuid	2 years	This domain of this cookie is owned by Vimeo. This cookie is used by vimeo to collect tracking information. It sets a unique ID to embed videos to the website.
_ga	2 years	This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors.
_gat_UA-26689388-1	1 minute	This is a pattern type cookie set by Google Analytics, where the pattern element on the name contains the unique identity number of the account or website it relates to. It appears to be a variation of the _gat cookie which is used to limit the amount of data recorded by Google on high traffic volume websites.
_gid	1 day	This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visted in an anonymous form.

Cookie	Duration	Description
IDE	1 year 24 days	Used by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
test_cookie	15 minutes	This cookie is set by doubleclick.net. The purpose of the cookie is to determine if the user's browser supports cookies.
VISITOR_INFO1_LIVE	5 months 27 days	This cookie is set by Youtube. Used to track the information of the embedded YouTube videos on a website.
YSC	session	This cookies is set by Youtube and is used to track the views of embedded videos.
yt-remote-connected-devices	never	These cookies are set via embedded youtube-videos.
yt-remote-device-id	never	These cookies are set via embedded youtube-videos.
yt.innertube::nextId	never	These cookies are set via embedded youtube-videos.
yt.innertube::requests	never	These cookies are set via embedded youtube-videos.

Cookie	Duration	Description
charitable_session	1 day	No description available.
cookielawinfo-checkbox-functional	1 year	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
debug	never	No description available.
socialsnap_viewed_1052	session	No description
socialsnap_viewed_1057	session	No description
socialsnap_viewed_1205	session	No description
socialsnap_viewed_1253	session	No description
socialsnap_viewed_1294	session	No description
socialsnap_viewed_13	session	No description
socialsnap_viewed_1374	session	No description
socialsnap_viewed_177	session	No description
socialsnap_viewed_1888	session	No description
socialsnap_viewed_1889	session	No description
socialsnap_viewed_1890	session	No description
socialsnap_viewed_1958	session	No description
socialsnap_viewed_201	session	No description
socialsnap_viewed_205	session	No description
socialsnap_viewed_207	session	No description
socialsnap_viewed_209	session	No description
socialsnap_viewed_211	session	No description
socialsnap_viewed_213	session	No description
socialsnap_viewed_217	session	No description
socialsnap_viewed_2195	session	No description
socialsnap_viewed_2197	session	No description
socialsnap_viewed_2199	session	No description
socialsnap_viewed_2201	session	No description
socialsnap_viewed_2203	session	No description
socialsnap_viewed_2205	session	No description
socialsnap_viewed_2207	session	No description
socialsnap_viewed_221	session	No description
socialsnap_viewed_2227	session	No description
socialsnap_viewed_225	session	No description
socialsnap_viewed_227	session	No description
socialsnap_viewed_2353	session	No description
socialsnap_viewed_26	session	No description
socialsnap_viewed_2654	session	No description
socialsnap_viewed_2656	session	No description
socialsnap_viewed_2659	session	No description
socialsnap_viewed_2678	session	No description
socialsnap_viewed_271	session	No description

THANC’s Mission

THANC’s Mission